Shenyang Xingqi Pharmaceutical experienced double increases in revenue and net profit last year, with short-term loans significantly rising compared to the beginning of the year | Interpretations
In 2024, both revenue and Net income increased, but there was a significant drop in Net income in the fourth quarter. Throughout the year, multiple loans were taken from Banks for the company's daily Operation turnover, with short-term borrowings exceeding 0.2 billion by the end of the year.
Vitamin prices have fallen, but it has not impacted performance; Zhejiang Nhu and Brother Enterprises Holding's Q1 performance remained basically stable compared to the previous quarter | Interpretations
① Zhejiang Nhu and Brother Enterprises Holding achieved a strong start in their performance in the first quarter of this year; ② Due to the influence of the order cycle, the price drop in Vitamins has not yet significantly impacted manufacturers' performance in the first quarter of this year; ③ In April, Vitamin prices continued to decline, putting short-term pressure on manufacturers' performance.
Guangzhou Wondfo Biotech: Expanding business in developing countries to hedge risks in the US market | Directly addressing the Earnings Conference.
① Guangzhou Wondfo Biotech responded in the Earnings Conference that the expansion of Business in developing countries and the growth of domestic Business can effectively hedge against potential risks in the USA Business. ② Wang Jihua believes that starting in 2024, the domestic POCT market will stabilize and recover.
Basically not affected by the USA tariff event. Jiangsu Nhwa Pharmaceutical: Continuing to pay attention to the progress of provincial collective procurement｜Direct coverage of the Earnings Conference.
① Jiangsu Nhwa Pharmaceutical stated that the possibility of national-level collective procurement for its products is relatively small, but there is uncertainty in some local organized procurements; ② Regarding the USA's tariff actions, Jiangsu Nhwa Pharmaceutical believes that since the company's import and export business volume is very small, it is basically not affected.
Brokerage morning meeting highlights: Countermeasures against tariffs boost Shenzhen Agricultural Products Group prices, the planting chain directly benefits.
At today's Brokerage morning meeting, CITIC SEC believes that countermeasures against tariffs boost the prices of Shenzhen Agricultural Products Group, which directly benefits the planting chain; HAITONG SEC proposed a bullish view on the relative yields of the Banks Sector in April; Galaxy Securities stated that it focuses on Gold and countermeasures against rare earths.
Bidding farewell to the "Ten Thousand Stores Era," China National Accord Medicines Corporation's retail Sector reported a net loss exceeding 1.1 billion yuan | Interpretations.
① In 2024, both revenue and Net income of China National Accord Medicines Corporation have declined, with the retail Sector turning to a loss year-on-year. ② Within half a year, the total number of Guoda Pharmacy stores sharply decreased to 9,569, with over 1,200 directly-operated stores closed.
